NCT06336070 Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study
| NCT ID | NCT06336070 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Valencia |
| Condition | Breast Cancer Female |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2024-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed of relapse free-cancer (RFC) or patients not diagnosed of any cancer at least the last 15 years (CG) * Aged between 35 and 75 years * Diagnostic of breast cancer (i.e., including ductal carcinoma, invasive carcinoma, triple negative; RFC) or physiological menopause (CG) * Not participating in a nutritional/dietary intervention * Not being physically active (i.e., not to be participating in any physical exercise program in the last 3 months, or performing less than 600 metabolic equivalents (METS)/week of moderate-vigorous physical activity). * To be capable and willing to provide informed consent * Not to suffer from any specific condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise intervention (i.e., determined by the research staff). Exclusion Criteria: * Medical contraindication for being engaged in an exercise. * Additional surgery planned within the intervention * Consuming usually betablocker or any drugs alterning nervous system functioning * History of another primary invasive cancer (RFC) or suffer a serious chronic illness (CG) * To present any of the following cardiac conditions: (i) myocardial infarction or coronary revascularization procedure within prior 3 months, (ii) uncontrolled hypertension (i.e., systolic ≥180 mmHg or diastolic ≥100 mmHg), (iii) uncontrolled arrhythmias (iv) valvular disease clinically significant, (v) decompensated heart failure or (vi) to suffer from known aortic aneurysm.
Contact & Investigator
Cristina Blasco Lafarga, Tenured Professor
PRINCIPAL INVESTIGATOR
University of Valencia
Frequently Asked Questions
Who can join the NCT06336070 clinical trial?
This trial is open to female participants only, aged 35 Years or older, up to 75 Years, studying Breast Cancer Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06336070 currently recruiting?
Yes, NCT06336070 is actively recruiting participants. Contact the research team at m.cristina.blasco@uv.es for enrollment information.
Where is the NCT06336070 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT06336070 clinical trial?
NCT06336070 is sponsored by University of Valencia. The principal investigator is Cristina Blasco Lafarga, Tenured Professor at University of Valencia. The trial plans to enroll 56 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.